AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy
In the context of future adeno-associated viral (AAV)-based clinical trials for Duchenne myopathy, AAV genome fate in dystrophic muscles is of importance considering the viral capsid immunogenicity that prohibits recurring treatments. We showed that AAV genomes encoding non-therapeutic U7 were lost...
Główni autorzy: | Le Hir, M, Goyenvalle, A, Peccate, C, Précigout, G, Davies, K, Voit, T, Garcia, L, Lorain, S |
---|---|
Format: | Journal article |
Język: | English |
Wydane: |
2013
|
Podobne zapisy
-
AAV-U7snRNA mediated multi exon-skipping for Duchenne muscular dystrophy
od: Goyenvalle, A, i wsp.
Wydane: (2010) -
AAV-U7snRNA mediated multi exon-skipping for Duchenne muscular dystrophy
od: Goyenvalle, A, i wsp.
Wydane: (2011) -
Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping
od: Goyenvalle, A, i wsp.
Wydane: (2012) -
Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping.
od: Goyenvalle, A, i wsp.
Wydane: (2012) -
Long-Term Efficacy of AAV9-U7snRNA-Mediated Exon 51 Skipping in mdx52 Mice
od: Philippine Aupy, i wsp.
Wydane: (2020-06-01)